Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how
clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar …

Chimeric antigen receptor (CAR-T) therapy has marked a paradigm shift in the treatment of
hematological malignancies and represent a promising growing field also in solid tumors …

Chimeric antigen receptor (CAR) T-cell therapy is one of the most innovative therapies for
haematological malignancies to emerge in a generation. Clinical studies have shown that a …

Chimeric antigen receptor-engineered T (CAR-T) cell immunotherapy has been successful
in treating many types of hematological malignancies. CAR-T therapy, however, has been …

Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of
certain hematological malignancies. While CAR-T cells have produced robust responses in …

Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option
for people with previously refractory B cell malignancies and are under development for a …

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of
immunotherapy for the treatment of hematologic malignancies. The two primary toxicities …

With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles
are evolving. There is an urgent and unmet need of approaches to optimally manage …

Chimeric antigen receptor (CAR) T cell therapy has become an indispensable tool in the
treatment of advanced malignancy, however, it is associated with significant neurologic …

Chimeric antigen receptor (CAR) T-cell therapy is an emerging highly effective treatment for
refractory haematological malignancies. Unfortunately, its therapeutic benefit may be …